- Home
- LUCY vs RNAZ Comparison
LUCY vs RNAZ Comparison
Compare LUCY & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | RNAZ |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 5.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LUCY | RNAZ |
|---|---|---|
| Price | $1.01 | $6.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 78.6K | 7.5K |
| Earning Date | 05-14-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $175.92 | N/A |
| Revenue Next Year | $205.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $5.56 |
| 52 Week High | $3.54 | $20.99 |
Technical Indicators
Market Signals| Indicator | LUCY | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 48.86 | 22.37 |
| Support Level | N/A | N/A |
| Resistance Level | $1.17 | $9.37 |
| Average True Range (ATR) | 0.05 | 0.62 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 57.67 | 17.48 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.